← Retour à la une
Océanie · Marchés régionaux · Stockhead

Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer

Publié par Stockhead · Australie il y a 4 h
Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer
Stockhead

Résumé détaillé

Self-confessed science nerd Dr Michael Baker has restarted the engine of Percheron Therapeutics with the aim of getting the oncology ... Read More The post Dr Boreham’s Crucible:…

Percheron has revived itself as an oncology play. Pic: Tim Boreham/supplied

Dr Michael Baker, the new CEO of Percheron Therapeutics (ASX:PER), describes himself as “pretty boring, but in a good way”.

“I just love high-quality science with a disproportionate chance of success in a field I have a tremendous interest in.”

Boring? We would still strike up a chat with him at a party, albeit after a second drink.

This alleged dullness made Baker a walk-up start to head Percheron, which has revived itself as an oncology play after a catastrophic Duchenne muscular dystrophy trial (see below).

Baker was fresh from a six-year stint at Arovella Therapeutics, which he re-engineered from unsuccessful spray-delivery drug play Suda Pharmaceuticals to an early-stage cancer cell therapy developer.

Baker’s Percheron appointment is also notable because he eschewed a number of better-paid, bigger roles for the buzz of early-stage drug development.

“I don’t want to sound like a twerp, but I was quite lucky in that I got a number of opportunities to explore and some of them were quite sizeable,” he said.

“They had a lot of money, [but] I actually didn’t find it all that interesting.

Début de l'article, extrait de Stockhead. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Stockhead Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stockhead.com.au)

À lire aussi